Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9254267 | OCULAR THERAPEUTIX | Composite hydrogel drug delivery systems |
Sep, 2024
(5 months from now) | |
US8563027 | OCULAR THERAPEUTIX | Drug delivery through hydrogel plugs |
Feb, 2030
(5 years from now) | |
US8409606 | OCULAR THERAPEUTIX | Drug delivery through hydrogel plugs |
May, 2030
(6 years from now) | |
US11458041 | OCULAR THERAPEUTIX | Punctal plug and bioadhesives |
Nov, 2037
(13 years from now) |
Dextenza is owned by Ocular Therapeutix.
Dextenza contains Dexamethasone.
Dextenza has a total of 4 drug patents out of which 0 drug patents have expired.
Dextenza was authorised for market use on 30 November, 2018.
Dextenza is available in insert;ophthalmic dosage forms.
Dextenza can be used as treatment of ocular itching associated with allergic conjunctivitis; treatment of ocular inflammation and pain following ophthalmic surgery, dextenza is approved for the treatment of ocular pain following ophthalmic surgery.
The generics of Dextenza are possible to be released after 16 November, 2037.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication (I) | Oct 7, 2024 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 30 November, 2018
Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery; Treatment of ocular itching associated with allergic conjunctivitis; Treatment of ocular inflammation and pain follo...
Dosage: INSERT;OPHTHALMIC